May 14, 2020 -- Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline.
Boehringer Ingelheim will be responsible for clinical, regulatory, and commercial development of the acquired programs. The acquisition transfers assets targeting tumor stromal and myeloid cells.
The first program, developing an antibody inhibitor of periostin, targets cold tumors and is in late preclinical development. The second program, for development of a myeloid cell regulator, enhances antitumor T-cell function and complements Boehringer Ingelheim's existing portfolio.
Northern Biologics will retain its name and continue to drive preclinical research for MSC-1, an anti-LIF 1 antibody candidate. Northern Biologics was established in Toronto in 2014 by founding investor Versant Ventures.
Copyright © 2020 scienceboard.net